OliX Pharmaceuticals, Inc

KOSDAQ:A226950 Stock Report

Market Cap: ₩2.5t

OliX Pharmaceuticals Future Growth

Future criteria checks 0/6

OliX Pharmaceuticals's revenue and earnings are forecast to decline at 19.8% and 30.1% per annum respectively while EPS is expected to decline by 31.3% per annum.

Key information

-30.1%

Earnings growth rate

-31.33%

EPS growth rate

Biotechs earnings growth25.2%
Revenue growth rate-19.8%
Future return on equityn/a
Analyst coverage

Low

Last updated04 Mar 2026

Recent future growth updates

No updates

Recent updates

Analysis Article • Dec 13

Is OliX Pharmaceuticals (KOSDAQ:226950) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Analysis Article • Jul 07

Is OliX Pharmaceuticals (KOSDAQ:226950) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Mar 21

Is OliX Pharmaceuticals (KOSDAQ:226950) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Jan 29

The Price Is Right For OliX Pharmaceuticals, Inc (KOSDAQ:226950) Even After Diving 27%

Unfortunately for some shareholders, the OliX Pharmaceuticals, Inc ( KOSDAQ:226950 ) share price has dived 27% in the...
Analysis Article • Dec 07

OliX Pharmaceuticals, Inc (KOSDAQ:226950) Looks Just Right With A 34% Price Jump

Despite an already strong run, OliX Pharmaceuticals, Inc ( KOSDAQ:226950 ) shares have been powering on, with a gain of...
Analysis Article • Nov 15

OliX Pharmaceuticals (KOSDAQ:226950) Is Making Moderate Use Of Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Oct 09

OliX Pharmaceuticals, Inc (KOSDAQ:226950) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

OliX Pharmaceuticals, Inc ( KOSDAQ:226950 ) shares have continued their recent momentum with a 27% gain in the last...
Analysis Article • Aug 22

Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower

OliX Pharmaceuticals, Inc ( KOSDAQ:226950 ) shares have had a horrible month, losing 27% after a relatively good period...
Analysis Article • Jul 22

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Jun 25

It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

Unfortunately for some shareholders, the OliX Pharmaceuticals, Inc ( KOSDAQ:226950 ) share price has dived 36% in the...
Analysis Article • Apr 13

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Feb 17

Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

It's been a soft week for OliX Pharmaceuticals,Inc ( KOSDAQ:226950 ) shares, which are down 14%. Despite this, the...

Earnings and Revenue Growth Forecasts

KOSDAQ:A226950 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202712,500-25,000-33,000-29,0002
12/31/20268,000-31,000-34,000-26,0001
3/31/202617,263-12,248-22,607-20,940N/A
12/31/202514,667-15,743-17,757-15,900N/A
9/30/202510,181-43,297-16,243-11,895N/A
6/30/20257,537-45,139-31,704-22,364N/A
3/31/20255,885-45,519-34,587-22,294N/A
12/31/20245,677-40,659-41,680-28,045N/A
9/30/202416,138-25,302-34,977-20,720N/A
6/30/202417,899-19,721-29,367-19,422N/A
3/31/202415,576-19,003-29,412-20,026N/A
12/31/202317,064-19,102-30,234-21,168N/A
9/30/20237,251-27,356-35,130-28,899N/A
6/30/20239,663-27,712-34,146-28,687N/A
3/31/20239,249-26,291-34,304-30,541N/A
12/31/20229,320-25,720-33,217-30,683N/A
9/30/20229,507-26,770-24,890-22,898N/A
6/30/20225,873-30,664-26,055-24,371N/A
3/31/20225,007-28,286-23,487-22,149N/A
12/31/20213,674-28,613-20,179-19,054N/A
9/30/20214,043-30,163-12,557-10,861N/A
6/30/20214,148-25,181-7,778-6,248N/A
3/31/20213,288-24,741-5,667-4,236N/A
12/31/20202,474-19,385-4,921-3,759N/A
9/30/20201,519-16,871-16,727-15,836N/A
6/30/2020958-16,147-18,313-17,053N/A
3/31/20201,196-14,885-16,184-15,188N/A
12/31/20191,130-14,353N/A-10,733N/A
9/30/20191,039-10,973N/A-7,853N/A
6/30/2019758-9,399N/A-6,669N/A
3/31/2019418-8,170N/A-5,769N/A
12/31/2018302-7,742N/A-8,359N/A
12/31/2017244-5,164N/A-4,787N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A226950 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: A226950 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: A226950 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: A226950's revenue is expected to decline over the next 3 years (-19.8% per year).

High Growth Revenue: A226950's revenue is forecast to decline over the next 3 years (-19.8% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A226950's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/12 08:37
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OliX Pharmaceuticals, Inc is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yeo NoraeHyundai Motor Securities Co. Ltd.
Hee Ryeong JungKyobo Securities Co., Ltd